Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SPRY 
ARS Pharmaceuticals, Inc (SPRY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/20/2025: SPRY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $31.33
1 Year Target Price $31.33
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.99% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 993.20M USD | Price to earnings Ratio - | 1Y Target Price 31.33 |
Price to earnings Ratio - | 1Y Target Price 31.33 | ||
Volume (30-day avg) 6 | Beta 0.84 | 52 Weeks Range 9.34 - 18.90 | Updated Date 10/19/2025 |
52 Weeks Range 9.34 - 18.90 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.48 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -42.74% | Operating Margin (TTM) -302.95% |
Management Effectiveness
Return on Assets (TTM) -13.85% | Return on Equity (TTM) -23.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 777465744 | Price to Sales(TTM) 8.84 |
Enterprise Value 777465744 | Price to Sales(TTM) 8.84 | ||
Enterprise Value to Revenue 6.92 | Enterprise Value to EBITDA -9.88 | Shares Outstanding 98826337 | Shares Floating 52091362 |
Shares Outstanding 98826337 | Shares Floating 52091362 | ||
Percent Insiders 16.83 | Percent Institutions 86.5 |
Upturn AI SWOT
ARS Pharmaceuticals, Inc
Company Overview
History and Background
ARS Pharmaceuticals, Inc. was founded in 2015. It is a biopharmaceutical company dedicated to developing and commercializing innovative products for severe allergic reactions. Their primary focus is on developing Neffy, an epinephrine nasal spray.
Core Business Areas
- Pharmaceutical Development and Commercialization: ARS Pharmaceuticals focuses on the development and commercialization of treatments for severe allergic reactions, particularly epinephrine nasal sprays.
Leadership and Structure
Richard Lowenthal is the co-founder, President, and CEO. The company has a typical biopharmaceutical organizational structure with departments focused on research, development, regulatory affairs, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Neffy (Epinephrine Nasal Spray): Neffy is ARS Pharmaceuticals' lead product candidate, designed as a needle-free, easy-to-use alternative to epinephrine auto-injectors for treating anaphylaxis. It is currently awaiting FDA approval. Competitors include Mylan (Viatris), Teva, and Amneal with their epinephrine auto-injector products like EpiPen and generics. Market share data unavailable, but the epinephrine market is dominated by auto-injectors.
Market Dynamics
Industry Overview
The industry comprises pharmaceutical companies developing and marketing treatments for allergic reactions, particularly anaphylaxis. The epinephrine market is dominated by auto-injectors, but there is a growing demand for easier-to-use and needle-free alternatives.
Positioning
ARS Pharmaceuticals aims to disrupt the epinephrine market by offering a needle-free nasal spray alternative. Their competitive advantage lies in the convenience and ease of use of Neffy.
Total Addressable Market (TAM)
The global epinephrine market is expected to reach several billion USD. ARS Pharmaceuticals aims to capture a significant portion of this TAM by offering a differentiated product.
Upturn SWOT Analysis
Strengths
- Innovative needle-free nasal spray technology
- Potential to disrupt the established epinephrine auto-injector market
- Strong intellectual property protection for Neffy
Weaknesses
- Reliance on FDA approval for Neffy
- Limited commercialization experience as a relatively young company
- Currently generates no revenue
Opportunities
- Growing awareness of anaphylaxis and the need for improved treatments
- Potential to expand Neffy's indications to other allergic reactions
- Partnerships with larger pharmaceutical companies for commercialization
Threats
- Regulatory hurdles and potential rejection of Neffy by the FDA
- Competition from established epinephrine auto-injector manufacturers
- Development of competing needle-free epinephrine delivery technologies
Competitors and Market Share
Key Competitors
- VTRS
- TEVA
- AMRX
Competitive Landscape
ARS Pharmaceuticals aims to compete with established players by offering a more convenient and user-friendly product. Their success depends on overcoming regulatory hurdles and effectively marketing Neffy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in R&D spending and preclinical/clinical development activities.
Future Projections: Future growth is heavily dependent on the FDA approval of Neffy and its subsequent commercial success. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include completing clinical trials for Neffy and preparing for potential commercial launch.
Summary
ARS Pharmaceuticals is a development-stage company with a promising needle-free epinephrine nasal spray, Neffy. Its success hinges on FDA approval and subsequent commercialization. The company faces significant competition from established players in the epinephrine market, and their financials are currently pre-revenue. The company needs to secure approval and compete effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ARS Pharmaceuticals, Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-12-04 | Co-Founder, President, CEO & Director Mr. Richard E. Lowenthal M.B.A., M.S., MSMSEL | ||
Sector Healthcare | Industry Biotechnology | Full time employees 162 | Website https://ars-pharma.com |
Full time employees 162 | Website https://ars-pharma.com | ||
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.